Immatics N.V.
Status: Publicly traded
Direct answer
Immatics N.V. is publicly traded on NASDAQ under the ticker IMTX.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio...
Can you invest in Immatics N.V.?
Yes. Immatics N.V. is publicly traded on NASDAQ under the ticker IMTX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immatics N.V.
Detailed equity research is provided by MarketSnap.